JPH08510720A - 経皮的薬物送り出しのための組成物及び方法 - Google Patents
経皮的薬物送り出しのための組成物及び方法Info
- Publication number
- JPH08510720A JPH08510720A JP6518085A JP51808594A JPH08510720A JP H08510720 A JPH08510720 A JP H08510720A JP 6518085 A JP6518085 A JP 6518085A JP 51808594 A JP51808594 A JP 51808594A JP H08510720 A JPH08510720 A JP H08510720A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical agent
- skin
- nucleotide
- oligonucleotide
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Electrotherapy Devices (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US946393A | 1993-01-27 | 1993-01-27 | |
| US7778693A | 1993-06-14 | 1993-06-14 | |
| US7729693A | 1993-06-14 | 1993-06-14 | |
| US10732993A | 1993-08-16 | 1993-08-16 | |
| US08/009,463 | 1993-08-16 | ||
| US08/107,329 | 1993-08-16 | ||
| US08/077,786 | 1993-08-16 | ||
| US08/077,296 | 1993-08-16 | ||
| PCT/US1994/000896 WO1994017792A2 (fr) | 1993-01-27 | 1994-01-26 | Compositions et procedes d'administration transdermique de medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08510720A true JPH08510720A (ja) | 1996-11-12 |
Family
ID=27485882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6518085A Pending JPH08510720A (ja) | 1993-01-27 | 1994-01-26 | 経皮的薬物送り出しのための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0683668A4 (fr) |
| JP (1) | JPH08510720A (fr) |
| AU (1) | AU6764794A (fr) |
| CA (1) | CA2153243A1 (fr) |
| WO (1) | WO1994017792A2 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6348449B1 (en) | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
| US5942395A (en) * | 1997-05-09 | 1999-08-24 | Universite De Montreal | Hybrid ribozymes and methods of use |
| DE19814257A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
| BR9816014A (pt) * | 1998-09-01 | 2001-05-08 | Idea Ag | Transporte eletricamente controlado de penetrantes carregados através de barreiras |
| US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
| US6713309B1 (en) | 1999-07-30 | 2004-03-30 | Large Scale Proteomics Corporation | Microarrays and their manufacture |
| EP2046954A2 (fr) | 2006-07-31 | 2009-04-15 | Curevac GmbH | Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant |
| US8530436B2 (en) | 2007-01-29 | 2013-09-10 | Transderm, Inc. | Methods and compositions for transdermal delivery of nucleotides |
| WO2009030254A1 (fr) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes d'arn et de peptides cationiques pour transfection et immunostimulation |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| WO2010037408A1 (fr) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2013113326A1 (fr) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
| AU609769B2 (en) * | 1987-02-10 | 1991-05-09 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of proteins |
| US5085749A (en) * | 1989-03-14 | 1992-02-04 | Massachusetts Institute Of Technology | Dynamically controlled membrane |
| WO1990012022A1 (fr) * | 1989-03-31 | 1990-10-18 | University Patents, Inc. | Phosphorodithioates de polynucleotides servant d'agents therapeutiques contre des infections retrovirales |
| US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
-
1994
- 1994-01-26 AU AU67647/94A patent/AU6764794A/en not_active Abandoned
- 1994-01-26 WO PCT/US1994/000896 patent/WO1994017792A2/fr not_active Ceased
- 1994-01-26 JP JP6518085A patent/JPH08510720A/ja active Pending
- 1994-01-26 EP EP94915749A patent/EP0683668A4/fr not_active Withdrawn
- 1994-01-26 CA CA002153243A patent/CA2153243A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0683668A1 (fr) | 1995-11-29 |
| WO1994017792A2 (fr) | 1994-08-18 |
| AU6764794A (en) | 1994-08-29 |
| CA2153243A1 (fr) | 1994-08-18 |
| EP0683668A4 (fr) | 1997-12-29 |
| WO1994017792A3 (fr) | 1994-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH08510720A (ja) | 経皮的薬物送り出しのための組成物及び方法 | |
| Akhtar et al. | Interactions of antisense DNa oliginucletide analogs with phospholid membranes (liposomes) | |
| Capaccioli et al. | Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum | |
| TWI225412B (en) | Liposome-entrapped polynucleotide composition and method | |
| US6858226B2 (en) | Fusogenic lipids and vesicles | |
| US6287591B1 (en) | Charged therapeutic agents encapsulated in lipid particles containing four lipid components | |
| EP1059092B1 (fr) | Utilisation de complexes de liposomes cationiques et de polydéoxyribonucléotides comme médicaments | |
| Dujardin et al. | Topical gene transfer into rat skin using electroporation | |
| Wilson et al. | Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles | |
| US20030229040A1 (en) | Cationic liposomal delivery system and therapeutic use thereof | |
| EP0983513A1 (fr) | Liposomes renfermant des oligonucleotides | |
| KR100723852B1 (ko) | 핵산 및 약물 전달용 중성-양이온성 지질 | |
| US6559129B1 (en) | Cationic liposomal delivery system and therapeutic use thereof | |
| JP2008518998A (ja) | 活性物質としてオリゴヌクレオチドを含む医薬組成物におけるまたはそれに関する改善 | |
| WO1998013024A2 (fr) | Systeme hyaluronique d'administration de medicaments | |
| US7262173B2 (en) | Chemosensitizing with liposomes containing oligonucleotides | |
| JP5674923B2 (ja) | アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法 | |
| Goodchild et al. | The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits | |
| US6897200B1 (en) | Oligonucleotide delivery systems for camptothecins | |
| CN106102773A (zh) | 组合物 | |
| Nolen III et al. | Percutaneous penetration of methyl phosphonate antisense oligonucleotides | |
| KR102306384B1 (ko) | 피부 투과성 핵산 복합체를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물 | |
| JP2003523377A (ja) | 分子の経皮的又は皮内送達のための方法 | |
| AU2001241743A1 (en) | Method for transdermal or intradermal delivery of molecules | |
| Preat et al. | Topical delivery of nucleic acids in the skin |